Zura Bio Statistics
Total Valuation
Zura Bio has a market cap or net worth of $410.15 million. The enterprise value is $205.01 million.
| Market Cap | 410.15M |
| Enterprise Value | 205.01M |
Important Dates
The next estimated earnings date is Thursday, November 12, 2026, before market open.
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Zura Bio has 95.83 million shares outstanding. The number of shares has increased by 17.17% in one year.
| Current Share Class | 95.83M |
| Shares Outstanding | 95.83M |
| Shares Change (YoY) | +17.17% |
| Shares Change (QoQ) | +12.99% |
| Owned by Insiders (%) | 11.55% |
| Owned by Institutions (%) | 59.79% |
| Float | 45.08M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.14 |
| P/TBV Ratio | 2.08 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.90
| Current Ratio | 12.90 |
| Quick Ratio | 12.57 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -51.01% and return on invested capital (ROIC) is -34.49%.
| Return on Equity (ROE) | -51.01% |
| Return on Assets (ROA) | -31.23% |
| Return on Invested Capital (ROIC) | -34.49% |
| Return on Capital Employed (ROCE) | -47.06% |
| Weighted Average Cost of Capital (WACC) | 4.30% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.91M |
| Employee Count | 40 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -81,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +19.55% in the last 52 weeks. The beta is 0.01, so Zura Bio's price volatility has been lower than the market average.
| Beta (5Y) | 0.01 |
| 52-Week Price Change | +19.55% |
| 50-Day Moving Average | 5.07 |
| 200-Day Moving Average | 5.31 |
| Relative Strength Index (RSI) | 44.66 |
| Average Volume (20 Days) | 3,592,510 |
Short Selling Information
The latest short interest is 9.37 million, so 9.77% of the outstanding shares have been sold short.
| Short Interest | 9.37M |
| Short Previous Month | 9.34M |
| Short % of Shares Out | 9.77% |
| Short % of Float | 20.78% |
| Short Ratio (days to cover) | 5.44 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -92.75M |
| Pretax Income | -85.82M |
| Net Income | -116.45M |
| EBITDA | -92.69M |
| EBIT | -92.75M |
| Earnings Per Share (EPS) | -$1.09 |
Balance Sheet
The company has $205.13 million in cash and no debt, with a net cash position of $205.13 million or $2.14 per share.
| Cash & Cash Equivalents | 205.13M |
| Total Debt | n/a |
| Net Cash | 205.13M |
| Net Cash Per Share | $2.14 |
| Equity (Book Value) | 197.09M |
| Book Value Per Share | 2.07 |
| Working Capital | 194.18M |
Cash Flow
In the last 12 months, operating cash flow was -$77.55 million and capital expenditures -$86,000, giving a free cash flow of -$77.63 million.
| Operating Cash Flow | -77.55M |
| Capital Expenditures | -86,000 |
| Depreciation & Amortization | 61,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -77.63M |
| FCF Per Share | -$0.81 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Zura Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -17.17% |
| Shareholder Yield | -17.17% |
| Earnings Yield | -28.39% |
| FCF Yield | -18.93% |
Analyst Forecast
The average price target for Zura Bio is $18.00, which is 320.56% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $18.00 |
| Price Target Difference | 320.56% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |